Literature DB >> 16410047

Primary open-angle glaucoma patients have reduced levels of blood docosahexaenoic and eicosapentaenoic acids.

Hongmei Ren1, Nwabueze Magulike, Kebreab Ghebremeskel, Michael Crawford.   

Abstract

The aetiology of primary open-angle glaucoma (POAG), which is the commonest cause of non-remediable blindness and visual impairment, is not well understood. Nevertheless, increased intraocular pressure, and vascular factors such as ocular blood flow deficits are thought to be risk factors. There is evidence of decreased optic nerve blood velocity and increased red blood cell aggregability in POAG. These factors are influenced by fatty acids. We have investigated if glaucoma patients have abnormal blood fatty acid composition. Patients with POAG (n=10) and their healthy siblings (n=8) were enrolled. Compared with their healthy siblings, the glaucoma patients had reduced eicosapentaenoic (EPA, P<0.01), and docosahexaenoic (DHA, P<0.05) fatty acids and total omega3 long-chain polyunsaturated fatty acids (LCPUFA) (P<0.05) in red cell choline phosphoglycerides (CPG); decreased EPA (P<0.05) in ethanolamine phosphoglycerides (EPG); lower EPA (P<0.05) and total omega3 LCPUFA (P<0.05) in serine phosphoglycerides (SPG). Similarly, they had reduced EPA, DHA and total omega3 LCPUFA in plasma CPG (P<0.005) and triglycerides (P<0.05). These findings may be significant, since EPA and DHA could modulate impaired systemic microcirculation and ocular blood flow and optic neuropathy, which are the main physiological changes associated with glaucoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410047     DOI: 10.1016/j.plefa.2005.11.007

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  25 in total

Review 1.  [Functional disorders in the chronological progression of glaucoma].

Authors:  Carl Erb
Journal:  Ophthalmologe       Date:  2015-05       Impact factor: 1.059

2.  Phospholipid profiles of control and glaucomatous human aqueous humor.

Authors:  Genea Edwards; Katyayini Aribindi; Yenifer Guerra; Richard K Lee; Sanjoy K Bhattacharya
Journal:  Biochimie       Date:  2014-02-21       Impact factor: 4.079

3.  Association of Dietary Fatty Acid Intake With Glaucoma in the United States.

Authors:  Ye Elaine Wang; Victoria L Tseng; Fei Yu; Joseph Caprioli; Anne L Coleman
Journal:  JAMA Ophthalmol       Date:  2018-02-01       Impact factor: 7.389

4.  Biomarkers of primary open-angle glaucoma.

Authors:  Paul A Knepper; John R Samples; Beatrice Yjt Yue
Journal:  Expert Rev Ophthalmol       Date:  2010-12

5.  Essential fatty acids in the treatment of dry eye syndrome: A myth or reality?

Authors:  Ammar M Al Mahmood; Samar A Al-Swailem
Journal:  Saudi J Ophthalmol       Date:  2014-06-24

6.  Cod liver oil: a potential protective supplement for human glaucoma.

Authors:  Wen-Bin Huang; Qian Fan; Xiu-Lan Zhang
Journal:  Int J Ophthalmol       Date:  2011-12-18       Impact factor: 1.779

7.  Serum free fatty acids levels not associated with normal tension glaucoma.

Authors:  Kenya Yuki; Itaru Kimura; Kazuo Tsubota
Journal:  Clin Ophthalmol       Date:  2010-02-18

8.  Variability of serum oxidative stress biomarkers relative to biochemical data and clinical parameters of glaucoma patients.

Authors:  Kaya N Engin; Bülent Yemişci; Ulviye Yiğit; Ahmet Ağaçhan; Cihan Coşkun
Journal:  Mol Vis       Date:  2010-07-09       Impact factor: 2.367

9.  Metabolome-Wide Association Study of Primary Open Angle Glaucoma.

Authors:  L Goodwin Burgess; Karan Uppal; Douglas I Walker; Rachel M Roberson; ViLinh Tran; Megan B Parks; Emily A Wade; Alexandra T May; Allison C Umfress; Kelli L Jarrell; Brooklyn O C Stanley; John Kuchtey; Rachel W Kuchtey; Dean P Jones; Milam A Brantley
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-07       Impact factor: 4.799

Review 10.  Lifestyle, nutrition, and glaucoma.

Authors:  Louis R Pasquale; Jae Hee Kang
Journal:  J Glaucoma       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.